Smoking Cessation Drugs Are Safe
New research reduces concern that non-nicotine medications could cause neuropsychiatric issues.
An international team of investigators compared the smoking cessation aids varenicline (marketed as Chantix in the U.S.) and bupropion (Zyban) to the nicotine patch and a placebo.
As reported in the journal The Lancet, researchers discovered the medications were not associated with a significant increase in neuropsychiatric adverse events.
“There are one billion smokers in the world and nearly six million smoking-related deaths each year, but there are only three approved medication treatments for quitting: nicotine replacement therapies like the patch and the two non-nicotine medications, bupropion, and varenicline,” said Robert Anthenelli, M.D., professor of psychiatry, at University of California San Diego School of Medicine and first author of the study.
Anthenelli said the so-called EAGLES study is important because it prospectively examined the neuropsychiatric safety risks and quit-enhancing potential of the three medication classes versus placebo in a rigorous, adequately-sized, randomized controlled trial.
It is the result of a Food and Drug Administration (FDA) mandate following post-marketing reports suggesting varenicline and bupropion might cause adverse neuropsychiatric events, such as increased agitation, depression, hostility, or suicidal behavior.
The FDA requested that both medications carry boxed warnings in their labeling. This has resulted in limitation in use. The EAGLES study was funded by Pfizer and GlaxoSmithKline, makers of varenicline and bupropion, respectively, and designed in consultation with the FDA.
Authors sought to directly assess the safety and efficacy of varenicline and bupropion compared to the nicotine patch and to a placebo in smokers with and without psychiatric disorders.
Investigators conducted a randomized, controlled, double-blind trial in an examination of more than 8,000 smokers seeking to quit in 16 countries over a period from November 2011 to January 2015.
Trial participants, investigators and research personnel were blinded to who received which treatment.
“This is the first study to compare the safety and efficacy of the three first-line smoking cessation aids on the market, head-to-head, in smokers. It’s the largest double-blind smoking cessation medication trial to date,” said Anthenelli.
“And no study has done so in smokers with current or past psychiatric disorders who consume roughly 45 percent of the cigarettes sold in the U.S.”
In terms of safety, approximately two percent of non-psychiatric participants reported moderate or severe adverse neuropsychiatric events for any of the treatments. Specifically, 1.3 percent for varenicline, 2.2 percent for bupropion, 2.5 percent for the nicotine patch, and 2.4 percent for placebo.
In the cohort of participants with psychiatric disorders, moderate and severe adverse neuropsychiatric events were slightly higher across the board: 6.5 percent for varenicline, 6.7 percent for bupropion, 5.3 percent for the nicotine patch, and 4.9 percent for placebo.
Anthenelli said the risk difference in the incidence of serious neuropsychiatric adverse events for varenicline and bupropion was not significantly higher than placebo. However, psychiatric patients trying to stop smoking are likely to have more confounding or complicating factors in treatment and appear to have a harder time quitting.
The efficacy or success rate, measured as biochemically-confirmed continuous abstinence for weeks nine to 12 after treatment began, was broadly consistent with past research and predictions.
Regardless of participants’ psychiatric status, varenicline was found to be more effective at helping smokers achieve abstinence than bupropion, the patch or placebo; bupropion and patch were more effective than the placebo.
For all of the treatment groups, the most frequent adverse events were nausea, insomnia, abnormal dreams, and headache.
Nauert PhD, R. (2016). Smoking Cessation Drugs Are Safe. Psych Central. Retrieved on March 18, 2018, from https://psychcentral.com/news/2016/04/26/smoking-cessation-drugs-are-safe/102268.html